[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100413658":3},{"organization":4,"armGroups":7,"interventions":30,"overallOfficials":48,"centralContacts":53,"locations":61,"responsibleParty":252,"collaborators":254,"id":257,"slug":258,"hasResults":259,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":29,"eligibilityCriteria":263,"healthyVolunteers":259,"sex":264,"minAge":265,"maxAge":29,"enrollmentInfo":266,"targetDuration":29,"studyType":269,"phases":270,"briefSummary":272,"conditions":273,"keywords":29,"overallStatus":64,"whyStopped":29,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":284},{"fullName":5,"class":6},"Vastra Gotaland Region","OTHER_GOV",[8,15,21,26],{"label":9,"type":10,"description":11,"interventionNames":12},"Randomisation 1: Adenosine and Dipyridamole","ACTIVE_COMPARATOR","Adenosine infusion 70 µg\u002Fkg\u002Fmin for 3 hours, followed (first dose 60 minutes apart from the end of the adenosine infusion) by daily oral treatment with the adenosine reuptake inhibitor dipyridamole (200 mg b.i.d.) until normalization of Left Ventricular (LV) function (EF≥50%) is documented on the study-specific echocardiographic assessment at 48-96 hours or at any subsequent echocardiographic examination, or for 30+7 Days.",[13,14],"Drug: Adenosine","Drug: Dipyridamole 200 mg",{"label":16,"type":17,"description":18,"interventionNames":19},"Randomisation 1: Control","OTHER","Care as recommended by the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology.",[20],"Other: Care as recommended by the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology for takotsubo syndrome",{"label":22,"type":10,"description":23,"interventionNames":24},"Randomisation 2: Apixaban","Apixaban 5mg b.i.d. per oral until normalization of LV function (EF≥50%) is documented on the study-specific echocardiographic assessment at 48-96 hours or any subsequent echocardiographic examination, or for 30+7 Days.",[25],"Drug: Apixaban 5 mg Oral Tablet",{"label":27,"type":28,"description":29,"interventionNames":29},"Randomisation 2: No anticoagulant therapy","NO_INTERVENTION",null,[31,36,40,44],{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":29},"DRUG","Adenosine","Adenosine infusion 70 µg\u002Fkg\u002Fmin for 3 hours.",[9],{"type":32,"name":37,"description":38,"armGroupLabels":39,"otherNames":29},"Dipyridamole 200 mg","200 mg b.i.d",[9],{"type":32,"name":41,"description":42,"armGroupLabels":43,"otherNames":29},"Apixaban 5 mg Oral Tablet","5mg b.i.d",[22],{"type":17,"name":45,"description":46,"armGroupLabels":47,"otherNames":29},"Care as recommended by the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology for takotsubo syndrome","This treatment will vary depending on local routines and the degree of adherence to the recommendations.",[16],[49],{"name":50,"affiliation":51,"role":52},"Elmir Omerovic, MD PhD","Sahlgrenska University Hospital","PRINCIPAL_INVESTIGATOR",[54,59],{"name":50,"role":55,"phone":56,"phoneExt":57,"email":58},"CONTACT","31 3421000","+46","elmir@wlab.gu.se",{"name":60,"role":55,"phone":56,"phoneExt":57,"email":29},"Björn Redfors, MD, PhD",[62,77,88,101,119,135,151,162,170,178,189,200,211,222,233,241],{"facility":63,"status":64,"city":65,"state":29,"zip":29,"country":66,"countryCode":67,"cosmosGeoPoint":68,"geoPoint":73,"contacts":74},"Aarhus Universitetshospital","RECRUITING","Aarhus","Denmark","DK",{"type":69,"coordinates":70},"Point",[71,72],10.21076,56.15674,{"lat":72,"lon":71},[75],{"name":76,"role":55,"phone":29,"phoneExt":29,"email":29},"Steen Hvitfeldt Poulsen, MD",{"facility":78,"status":64,"city":79,"state":29,"zip":29,"country":66,"countryCode":67,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"Rigshospitalet","Copenhagen",{"type":69,"coordinates":81},[82,83],12.56553,55.67594,{"lat":83,"lon":82},[86],{"name":87,"role":55,"phone":29,"phoneExt":29,"email":29},"Lia Evi Bang, MD",{"facility":89,"status":64,"city":90,"state":29,"zip":29,"country":91,"countryCode":92,"cosmosGeoPoint":93,"geoPoint":97,"contacts":98},"Oslo University Hospital","Oslo","Norway","NO",{"type":69,"coordinates":94},[95,96],10.74609,59.91273,{"lat":96,"lon":95},[99],{"name":100,"role":55,"phone":29,"phoneExt":29,"email":29},"Njord Nordstrand, MD",{"facility":102,"status":64,"city":103,"state":104,"zip":105,"country":106,"countryCode":107,"cosmosGeoPoint":108,"geoPoint":112,"contacts":113},"Östersund Sjukhus","Östersund","Jämtland Härjedalen","831 27","Sweden","SE",{"type":69,"coordinates":109},[110,111],14.63566,63.1792,{"lat":111,"lon":110},[114,118],{"name":115,"role":55,"phone":116,"phoneExt":29,"email":117},"Fredrik Björklund, MD","063-14 75 00","fredrik.bjorklund@regionjh.se",{"name":115,"role":52,"phone":29,"phoneExt":29,"email":29},{"facility":120,"status":64,"city":121,"state":122,"zip":123,"country":106,"countryCode":107,"cosmosGeoPoint":124,"geoPoint":128,"contacts":129},"Region Jönköpings Län","Jönköping","Region Jönköping","55111",{"type":69,"coordinates":125},[126,127],14.15618,57.78145,{"lat":127,"lon":126},[130,134],{"name":131,"role":55,"phone":132,"phoneExt":29,"email":133},"Dario Gulin, MD","010-241 00 00","dario.gulin@rjl.se",{"name":131,"role":52,"phone":29,"phoneExt":29,"email":29},{"facility":136,"status":64,"city":137,"state":138,"zip":139,"country":106,"countryCode":107,"cosmosGeoPoint":140,"geoPoint":144,"contacts":145},"Norra Älvsborgs länssjukhus","Trollhättan","Västra Götalands Region","46173",{"type":69,"coordinates":141},[142,143],12.28864,58.28365,{"lat":143,"lon":142},[146,150],{"name":147,"role":55,"phone":148,"phoneExt":29,"email":149},"Imran Tahir, MD","010-435 00 00","imran.tahir@vgregion.se",{"name":147,"role":52,"phone":29,"phoneExt":29,"email":29},{"facility":152,"status":64,"city":153,"state":29,"zip":29,"country":106,"countryCode":107,"cosmosGeoPoint":154,"geoPoint":158,"contacts":159},"Region Dalarna","Falun",{"type":69,"coordinates":155},[156,157],15.62597,60.60357,{"lat":157,"lon":156},[160],{"name":161,"role":55,"phone":29,"phoneExt":29,"email":29},"Per Lundberg, MD",{"facility":163,"status":64,"city":164,"state":29,"zip":29,"country":106,"countryCode":107,"cosmosGeoPoint":165,"geoPoint":169,"contacts":29},"Sahlgrenska University Hospital, Department of Cardiology","Gothenburg",{"type":69,"coordinates":166},[167,168],11.96679,57.70716,{"lat":168,"lon":167},{"facility":171,"status":64,"city":164,"state":29,"zip":29,"country":106,"countryCode":107,"cosmosGeoPoint":172,"geoPoint":174,"contacts":175},"Skaraborg Hospital",{"type":69,"coordinates":173},[167,168],{"lat":168,"lon":167},[176],{"name":177,"role":55,"phone":29,"phoneExt":29,"email":29},"Lisa Brandin, MD",{"facility":179,"status":64,"city":180,"state":29,"zip":29,"country":106,"countryCode":107,"cosmosGeoPoint":181,"geoPoint":185,"contacts":186},"Region Skane Helsingborg Hospital","Helsingborg",{"type":69,"coordinates":182},[183,184],12.69437,56.04673,{"lat":184,"lon":183},[187],{"name":188,"role":55,"phone":29,"phoneExt":29,"email":29},"Sven-Erik Olsson, MD",{"facility":190,"status":64,"city":191,"state":29,"zip":29,"country":106,"countryCode":107,"cosmosGeoPoint":192,"geoPoint":196,"contacts":197},"Region Oestergoetland","Linköping",{"type":69,"coordinates":193},[194,195],15.62157,58.41086,{"lat":195,"lon":194},[198],{"name":199,"role":55,"phone":29,"phoneExt":29,"email":29},"Joakim Alfredsson, MD",{"facility":201,"status":64,"city":202,"state":29,"zip":29,"country":106,"countryCode":107,"cosmosGeoPoint":203,"geoPoint":207,"contacts":208},"Region Skane - Skanes Universitetssjukhus","Lund",{"type":69,"coordinates":204},[205,206],13.19321,55.70584,{"lat":206,"lon":205},[209],{"name":210,"role":55,"phone":29,"phoneExt":29,"email":29},"Nazim Isma, MD",{"facility":212,"status":64,"city":213,"state":29,"zip":29,"country":106,"countryCode":107,"cosmosGeoPoint":214,"geoPoint":218,"contacts":219},"Region Orebro lan","Örebro",{"type":69,"coordinates":215},[216,217],15.2066,59.27412,{"lat":217,"lon":216},[220],{"name":221,"role":55,"phone":29,"phoneExt":29,"email":29},"Anna Nordenskjöld, MD",{"facility":223,"status":64,"city":224,"state":29,"zip":29,"country":106,"countryCode":107,"cosmosGeoPoint":225,"geoPoint":229,"contacts":230},"Danderyds Hospital, Department of Cardiology","Stockholm",{"type":69,"coordinates":226},[227,228],18.06871,59.32938,{"lat":228,"lon":227},[231],{"name":232,"role":55,"phone":29,"phoneExt":29,"email":29},"Christina Ekenbäck, MD",{"facility":234,"status":64,"city":224,"state":29,"zip":29,"country":106,"countryCode":107,"cosmosGeoPoint":235,"geoPoint":237,"contacts":238},"Karolinska University Hospital, Huddinge, Department of Cardiology",{"type":69,"coordinates":236},[227,228],{"lat":228,"lon":227},[239],{"name":240,"role":55,"phone":29,"phoneExt":29,"email":29},"Loghman Henareh, MD",{"facility":242,"status":64,"city":243,"state":29,"zip":29,"country":106,"countryCode":107,"cosmosGeoPoint":244,"geoPoint":248,"contacts":249},"Umeå University Hospital, Department of Cardiology","Umeå",{"type":69,"coordinates":245},[246,247],20.25972,63.82842,{"lat":247,"lon":246},[250],{"name":251,"role":55,"phone":29,"phoneExt":29,"email":29},"Henrik Hagström, MD",{"type":253,"investigatorFullName":29,"investigatorTitle":29,"investigatorAffiliation":29,"oldNameTitle":29,"oldOrganization":29},"SPONSOR",[255],{"name":256,"class":17},"Göteborg University","100413658","phase-4-broken-swedeheart--optimized-pharmacological-treatment-for-broken-heart-takotsubo-syndrome-100413658",false,"NCT04666454","BROKEN-SWEDEHEART- Optimized Pharmacological Treatment for Broken Heart (Takotsubo) Syndrome.","BROKEN-SWEDEHEART- Optimized Pharmacological Treatment for Broken Heart (Takotsubo) Syndrome. A Multinational, Multicentre, Registry-based, Open-label, Randomized Controlled Trial.","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. A clinical diagnosis of TS (see definition 2.1), including an ejection fraction (EF) ˂ 50 % at baseline\n3. Written informed consent obtained\n\nExclusion Criteria:\n\n1. Previous randomization in the trial\n2. Any concomitant condition resulting in a life expectancy of less than one month\n3. Previously diagnosed left ventricular ejection fraction \\\u003C50%\n4. Known cardiomyopathy (except previous Takotsubo syndrome)\n5. Known hemodynamically significant valve disease (moderate or severe aortic\u002Fmitral regurgitation) or stenosis\n6. Heart transplant or left ventricular assist device recipient\n7. Most recent (within the most recent 3 months) haemoglobin ˂10 g\u002FdL\n8. Systolic blood pressure \\\u003C80 mm Hg at screening\n9. Estimated glomerular filtration rate \\\u003C30 mL\u002Fmin\u002F1.73m2\n10. Current dialysis\n11. Pregnancy or of childbearing potential who is not sterilized or is not using a medically accepted form of contraception\n12. Not suitable in the opinion of the investigator due to severe or terminal comorbidity with poor prognosis, or characteristics that may interfere with adherence to the trial protocol\n\n    Specific exclusion criteria for Randomization 1\n13. Any contra-indication for treatment with adenosine or dipyridamole (including AV-block II and III, sick-sinus syndrome in subjects who don´t have a functioning pacemaker, unstable angina, ongoing treatment with dipyridamole)\n14. Severe asthma (defined as asthma requiring medium or high-dose inhaled corticosteroids combined with other long-acting medications) and severe Chronic Obstructive Pulmonary Disease (COPD), (defined as FEV-1 ˂ 50 %)\n15. Ongoing treatment with dipyridamole\n16. Declined participation in study 1\n\nSpecific exclusion criteria for Randomization 2\n\n1. Any contra-indication for anticoagulant treatment.\n2. Current indication for treatment with, anticoagulant or dual antiplatelet therapy\n3. Declined participation in study 2","ALL","18 Years",{"count":267,"type":268},1000,"ESTIMATED","INTERVENTIONAL",[271],"PHASE4","The aim of this study is to document an optimized pharmacologic treatment for patients with Takotsubo Syndrome. There is currently no published documentation in a large number of patients. The study is a Randomized Registry Clinical Trial and in total 1000 patients registered in SWEDEHEART will be included.",[274],"Takotsubo Syndrome","2024-11-26",{"date":277,"type":278},"2024-12-02","ACTUAL",{"date":280,"type":278},"2020-12-14",{"date":282,"type":268},"2028-12",{"name":5,"class":6},16]